阿那白滞素治疗血液透析炎症的随机对照先导试验
ACTION试验是一项先导性、多中心、随机、安慰剂对照研究,纳入80例hsCRP≥2 mg/L的维持性血液透析患者,1:1随机接受阿那白滞素100 mg每周三次经透析通路给药或安慰剂治疗24周,并额外24周安全性监测。阿那白滞素耐受性良好,未增加感染或血细胞减少,严重不良事件与死亡 rates 与安慰剂相似;第24周hsCRP中位下降41% vs 6%,组间差异未达统计学显著,IL-6中位下降25% vs 0%有统计学意义,患者报告结局未见明显效果。
要点
- 阿那白滞素100 mg每周三次经透析通路给药24周,耐受性良好,未增加感染或血细胞减少。
- 严重不良事件发生率阿那白滞素组2.71 vs 安慰剂组2.74 events/patient-year,死亡0.12 vs 0.22 events/patient-year。
- 第24周hsCRP中位下降阿那白滞素组41% vs 安慰剂组6%,组间差异未达统计学显著;IL-6中位下降25% vs 0%,有统计学意义。
核心结论
- 阿那白滞素耐受性良好,未增加感染或血细胞减少;对CRP和IL-6的安全性和潜在疗效数据支持开展IL-1抑制改善血液透析患者结局的确证性试验。
研究设计与样本
- ACTION试验为多中心、随机、安慰剂对照的先导试验,纳入80例血浆高敏C反应蛋白(hsCRP)≥2 mg/L的血液透析患者,1:1随机分配至安慰剂组或阿那白滞素100 mg每周三次经血液透析通路给药组,治疗24周,另加24周治疗后安全性监测。
主要发现
- 严重不良事件发生率阿那白滞素组2.71 vs 安慰剂组2.74 events/patient-year,死亡发生率0.12 vs 0.22 events/patient-year,两组相似。
- 关注的不良事件(包括感染和血细胞减少)发生率阿那白滞素组0.48 vs 安慰剂组1.40 events/patient-year,阿那白滞素组显著更低。
- 可行性通过达到入组目标、80%的保留率和72%的给药完成率得到证明。
- 从基线至第24周hsCRP中位下降幅度阿那白滞素组41% vs 安慰剂组6%,组间差异未达统计学显著。
- IL-6中位下降幅度阿那白滞素组25% vs 安慰剂组0%,两组下降均有统计学意义;阿那白滞素对患者报告结局的效果不明显。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic inflammation is highly prevalent among patients receiving maintenance hemodialysis and is associated with morbidity and mortality. Inhibiting inflammation with anti-cytokine therapy has been proposed but not well studied in this population. Therefore, we conducted the ACTION trial, a pilot, multicenter, randomized, placebo-controlled trial of an IL-1 receptor antagonist, anakinra, to evaluate safety, tolerability, and feasibility, and explore efficacy. Eighty hemodialysis patients with plasma concentrations of high sensitivity C-reactive protein (hsCRP) 2 mg/L and above were randomized 1:1 to placebo or anakinra 100 mg, three times per week via the hemodialysis circuit for 24 weeks, with an additional 24 weeks of post-treatment safety monitoring. Efficacy outcomes included changes in hsCRP (primary), cytokines, and patient-reported outcomes. Rates of serious adverse events and deaths were similar with anakinra and placebo (serious adverse events: 2.71 vs 2.74 events/patient-year; deaths: 0.12 vs 0.22 events/patient-year). The rate of adverse events of interest (including infections and cytopenias) was significantly lower with anakinra than placebo (0.48 vs 1.40 events/patient-year). Feasibility was demonstrated by attaining the enrollment target, a retention rate of 80%, and administration of 72% of doses. The median decrease in hsCRP from baseline to Week 24 was 41% in the anakinra group and 6% in the placebo group, a between-group difference that was not statistically significant. For IL-6, the median decreases were significant: 25% and 0% in the anakinra and placebo groups, respectively. An effect of anakinra on patient-reported outcomes was not evident. Thus, anakinra was well tolerated and did not increase infections or cytopenias. The promising safety data and potential efficacy on CRP and IL-6 provide support for conducting definitive trials of IL-1 inhibition to improve outcomes in hemodialysis patients.
引用
- Dember LM, Hung A, Mehrotra R, et al. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney Int. 2022. PMID: 35863559. doi:10.1016/j.kint.2022.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。